<p>One area of a <i>ROS1</i>-rearranged tumor shows a solid area with intense immunostaining for ROS1 (a and c). Another area shows a predominantly signet ring cell feature with weaker immunostaining (b and d). Both areas were ALK IHC-negative (e and f).</p
Tumor cells with weak signal (intensity 1) are in the yellow circle, and tumor cells with strong sig...
(A) CDH3. There is no staining in the differentiated (*) or the less differentiated areas (#) of the...
(A). CDH3. There is no staining in the differentiated (*) or the less differentiates areas (#) of th...
<p>An <i>ROS1</i>-rearrangned tumor showed strong and diffuse cytoplasmic staining (a) (inset: <i>RO...
BACKGROUND: ROS1 rearrangement accounts for 1%-2% of non-small cell lung cancer (NSCLC) with a remar...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...
The variability of expression of tumour-associated antigens via either antigenic heterogeneity or an...
<p>Clinicopathologic Characteristics of <i>ROS1</i> and <i>ALK</i>-rearranged adenocarcinomas</p
<p>A tissue microarray representing 35 different types of primary cancers was probed with the anti-R...
<p>(A) Immunohistochemical staining of ROS1 showing negative immunoreactivity (B) <i>ROS1</i> break-...
<div><p><i>ROS1</i> rearrangement is a predictive biomarker for response to the tyrosine kinase inhi...
<p>A. 2+ score: weak-to-moderate complete membrane staining in more than 10% of tumor cells (objX40)...
<p>Scattered and dense staining pattern for two p53 immunoreactive tumors. (A) Scattered type. Singl...
(A) Representative IHC stainings of tumor specimens with a high number of CD8+ cells and a low numbe...
Tumor cells with weak signal (intensity 1) are in the yellow circle, and tumor cells with strong sig...
(A) CDH3. There is no staining in the differentiated (*) or the less differentiated areas (#) of the...
(A). CDH3. There is no staining in the differentiated (*) or the less differentiates areas (#) of th...
<p>An <i>ROS1</i>-rearrangned tumor showed strong and diffuse cytoplasmic staining (a) (inset: <i>RO...
BACKGROUND: ROS1 rearrangement accounts for 1%-2% of non-small cell lung cancer (NSCLC) with a remar...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...
The variability of expression of tumour-associated antigens via either antigenic heterogeneity or an...
<p>Clinicopathologic Characteristics of <i>ROS1</i> and <i>ALK</i>-rearranged adenocarcinomas</p
<p>A tissue microarray representing 35 different types of primary cancers was probed with the anti-R...
<p>(A) Immunohistochemical staining of ROS1 showing negative immunoreactivity (B) <i>ROS1</i> break-...
<div><p><i>ROS1</i> rearrangement is a predictive biomarker for response to the tyrosine kinase inhi...
<p>A. 2+ score: weak-to-moderate complete membrane staining in more than 10% of tumor cells (objX40)...
<p>Scattered and dense staining pattern for two p53 immunoreactive tumors. (A) Scattered type. Singl...
(A) Representative IHC stainings of tumor specimens with a high number of CD8+ cells and a low numbe...
Tumor cells with weak signal (intensity 1) are in the yellow circle, and tumor cells with strong sig...
(A) CDH3. There is no staining in the differentiated (*) or the less differentiated areas (#) of the...
(A). CDH3. There is no staining in the differentiated (*) or the less differentiates areas (#) of th...